CB1 Receptor: The Protein Behind Cannabinoid Signalling

A message that crosses the membrane

Something arrives at the outside of a cell. A protein sitting in the surface membrane picks it up and passes the information inward. That is the whole job of CB1, the receptor known in full as cannabinoid receptor type 1.

It belongs to a large family called G protein-coupled receptors, a class of surface proteins built around exactly this task: receive an external chemical signal, transmit it inward. CB1 was cloned in 1990 [1]. Within that class, it is the most abundant in the central nervous system, with lower densities recorded in some peripheral tissues [1].

If the endocannabinoid system has an anchor point, this is it. Much of the framing network for cannabinoid research grew out of work on this one receptor [1].

Why it carries a number

CB1 was the first receptor of the family to be named. Once a second one was described, the original was relabelled CB1, and both labels are still in use today. So the number is not a ranking. It's a record of the order in which the two were described. Nothing about the plant is written into the name. It describes a receptor, not a source.

Where the density sits

Ask where CB1 receptors are in the body and the honest answer is: in a lot of places, at very different concentrations. The central nervous system holds by far the highest share. Among the cannabinoid receptors described so far, CB1 is the one found in greatest abundance in central nervous tissue, and the 1990 work that defined the molecule also mapped where it is expressed [1].

Outside the brain and spinal cord, CB1 turns up in some peripheral tissues, at lower densities [1].

The regions where CB1 activity has been reported include those associated with mood, appetite, memory and movement [1]. That list describes where the signal is received, not what any one person will notice [1].

The pattern, not one address

One high-density site tells you little on its own. The interpretive weight sits with the distribution: which tissues, at which relative densities, in what pattern across the body [1]. A receptor found in many places, in different amounts, behaves like part of a network rather than a switch in a single organ. Researchers read the map rather than a pin. It is also why the same receptor keeps appearing in research fields that look unrelated.

From inference to a molecule

Before 1990, the receptor was a reasonable conclusion drawn from observed effects. Compounds did something in living tissue; something had to be receiving them. Then, in 1990, Matsuda and colleagues reported a cloned receptor sequence and showed it working in cells [1]. In plain terms: the inference became a defined molecule with a known sequence, one that could be produced in cells and examined directly [1].

That shift matters more than the date. A sequence can be compared. A protein that can be expressed in cultured cells can be studied on its own, apart from the tissue it came from. Everything that came later needed that starting point.

A paper still cited

The 1990 report is still the reference point for two separate things: the structure of the receptor, and its expression in cells [1]. Later work on ligands, distribution and signalling builds on that footing. Naming followed the same path. Once a second family member had been described, the receptor from the 1990 work took the CB1 label, and that is the label researchers still use. Read it today and it works less like an announcement than like a set of tools handed to everyone who came next [1].

Two sources of ligands

A ligand is simply a molecule that binds to a receptor. For CB1, the ones discussed most come from two origins. One is the body itself. The other is the cannabis plant.

That ordering surprises people who assume the receptor exists because of the plant. It doesn't. The body makes its own compounds that bind here, which is why the field talks about an endocannabinoid system at all [2].

Anandamide, isolated in 1992

In 1992, Devane and colleagues isolated a constituent of brain tissue that binds to the cannabinoid receptor and gave it a name: anandamide [2]. A body-produced molecule, with a structure on paper.

The second endogenous compound that comes up in almost every discussion of CB1 is 2-AG. The two are usually described together, as the pair of endocannabinoids with the longest research record.

The practical consequence of the 1992 finding is easy to state: the receptor is not plant-dependent [2]. It sits in tissue that produces its own ligands. That is also why cannabinoid research widened after 1992 [2]. Attention moved from single plant compounds towards a signalling system built into the body, with CB1 as its anchor point [1].

The plant side of the ledger

THC is the plant compound most discussed in connection with CB1, and it is the intoxicating one. That property is the reason hemp products sold in the EU are formulated and tested within legal THC limits, and are non-intoxicating as sold.

CBD is the other name that comes up, and here the picture is less tidy. How cannabidiol engages with CB1 has been characterised as less straightforward than a simple bind-and-activate description, and it stays an open question rather than a settled one. We would rather say that plainly than smooth it over.

Two compounds from the same plant, then, with two very different research positions. One with a well-documented relationship to the receptor and a legal threshold attached to it. One still being worked out. Same page, different columns.

At Cibdol we have been working with cannabinoids since 2014, from Basel, and the standard has not moved: report what the research found, name the gaps, cite the source, leave the conclusions to the reader. On a topic like CB1, that last part matters. The receptor is well described. Plenty of the questions around it are not.

What a receptor map can tell you

Receptor science produces a map. A map shows you where the roads go. It doesn't tell you what your journey will be like.

So: a high concentration of CB1 in a given region indicates one thing, which is that signals are received there [1]. It does not establish what a given compound will do in a given person, which is not something distribution data can answer [1]. That is a different question, addressed by human studies, and on many points the human evidence is still developing.

Worth holding onto, because the gap gets crossed casually. A receptor appears in tissue associated with appetite [1], and somewhere down the chain that turns into a promise about hunger. The receptor data never said that.

What the cited work does support is narrower and more useful. There is a defined protein, cloned in 1990, with a known sequence and a mapped distribution [1]. There are body-produced ligands, one of them named in 1992 [2]. There are plant compounds that interact with the same site, one of which carries a legal limit in EU hemp products.

Everything past that line is a question someone is still working on. Which, after all these years, is still the interesting part.